SUMMARY
The SARS-CoV-2 pandemic is currently leading to increasing numbers of COVID-19 patients all over the world. Clinical presentations range from asymptomatic, mild respiratory tract infection, to severe cases with acute respiratory distress syndrome, respiratory failure, and death. Reports on a dysregulated immune system in the severe cases calls for a better characterization and understanding of the changes in the immune system. Here, we profiled whole blood transcriptomes of 39 COVID-19 patients and 10 control donors enabling a data-driven stratification based on molecular phenotype. Neutrophil activation-associated signatures were prominently enriched in severe patient groups, which was corroborated in whole blood transcriptomes from an independent second cohort of 30 as well as in granulocyte samples from a third cohort of 11 COVID-19 patients. Comparison of COVID-19 blood transcriptomes with those of a collection of over 2,600 samples derived from 11 different viral infections, inflammatory diseases and independent control samples revealed highly specific transcriptome signatures for COVID-19. Further, stratified transcriptomes predicted patient subgroup-specific drug candidates targeting the dysregulated systemic immune response of the host.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ACA was supported by an intramural grant from the Department of Genomics & Immunoregulation at the LIMES Institute. The work of JLS and MMBB was supported by the German Research Foundation (DFG) under Germanys Excellence Strategy EXC2151 390873048 as well as by the Diet-Body-Brain Competence Cluster in Nutrition Research funded by the Federal Ministry of Education and Research (grant numbers 01EA1410C and 01EA1809C). JLS was further supported by the DFG under SCHU 950/8-1; GRK 2168, TP11; SFB704, the EU project SYSCID under grant number 733100. MGN was supported by a Spinoza grant of the Netherlands Organisation for Scientific Research and an ERC Advanced Grant (833247). The study was funded in part by the Hellenic Institute for the Study of Sepsis. EJG-B received funding from the FrameWork 7 program HemoSpec and from the Horizon2020 Marie-Curie project European Sepsis Academy (granted to the National and Kapodistrian University of Athens). JN was supported by the DFG (SFB TR57, SPP1937), the DZIF, and the Hector-Foundation (M89).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies were conducted under the 23/12.08.2019 approval of the Ethics Committee of Sotiria Athens General Hospital; and the 26.02.2019 approval of the Ethics Committee of ATTIKON University General Hospital.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study, including transcriptome data from 60 patients at multiple time points who granted informed consent to share such data, are made available at the European Genome-Phenome Archive (EGA) under accession number EGAS00001004503, which is hosted by the EBI and the CRG.
